Naureen Quibria

Stock Analyst at Capital One

(n/a)

# 4,624

Out of 5,006 analysts

9

Total ratings

11.11%

Success rate

-44.7%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Naureen Quibria

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BMEA Biomea Fusion	Initiates: Overweight	$25	$2.15	+1,062.79%	1	Aug 29, 2024
	IMMP Immutep	Initiates: Overweight	$10	$1.86	+437.63%	1	May 17, 2024
	ERAS Erasca	Initiates: Overweight	$8	$2.42	+230.58%	1	Mar 11, 2024
	CARM Carisma Therapeutics	Initiates: Overweight	$10	$0.26	+3,732.89%	1	Oct 3, 2023
	IMCR Immunocore Holdings	Initiates: Overweight	$84	$34.21	+145.54%	1	Aug 16, 2023
	DAWN Day One Biopharmaceuticals	Initiates: Overweight	$40	$7.95	+403.14%	1	Feb 8, 2023
	FENC Fennec Pharmaceuticals	Initiates: Overweight	$11	$9.88	+11.34%	1	Sep 7, 2022
	GNTA Genenta Science	Initiates: Buy	$21	$3.23	+550.15%	1	Jan 13, 2022
	KZIA Kazia Therapeutics	Initiates: Buy	$900	$6.56	+13,619.51%	1	Oct 14, 2021

Biomea Fusion

Aug 29, 2024

Initiates: Overweight

Price Target: $25

Current: $2.15

Upside: +1,062.79%

Immutep

May 17, 2024

Initiates: Overweight

Price Target: $10

Current: $1.86

Upside: +437.63%

Erasca

Mar 11, 2024

Initiates: Overweight

Price Target: $8

Current: $2.42

Upside: +230.58%

Carisma Therapeutics

Oct 3, 2023

Initiates: Overweight

Price Target: $10

Current: $0.26

Upside: +3,732.89%

Immunocore Holdings

Aug 16, 2023

Initiates: Overweight

Price Target: $84

Current: $34.21

Upside: +145.54%

Day One Biopharmaceuticals

Feb 8, 2023

Initiates: Overweight

Price Target: $40

Current: $7.95

Upside: +403.14%

Fennec Pharmaceuticals

Sep 7, 2022

Initiates: Overweight

Price Target: $11

Current: $9.88

Upside: +11.34%

Genenta Science

Jan 13, 2022

Initiates: Buy

Price Target: $21

Current: $3.23

Upside: +550.15%

Kazia Therapeutics

Oct 14, 2021

Initiates: Buy

Price Target: $900

Current: $6.56

Upside: +13,619.51%